[Dipotassium chlorazepate. Clinical reports on a new anxiolytic].
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000188:drug therapy; D001334:Automobile Driving; D002318:Cardiovascular Diseases / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy; D003975:Diazepam / Q000627:therapeutic use; D003984:Dibenzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004361:Drug Tolerance; D005239:Fear / Q000187:drug effects; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008620:Meprobamate / Q000627:therapeutic use; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy; D010919:Placebos; D011618:Psychotic Disorders / Q000188:drug therapy; D013881:Thioridazine / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D003984:Dibenzazepines; D010919:Placebos; D014149:Tranquilizing Agents; D008620:Meprobamate; D013881:Thioridazine; D003975:Diazepam
Dikalium-chlorazepat. Klinische Berichte über ein neues Anxiolyticum.